Drugs / Interferon Alfacon-1
Interferon Alfacon-1
also known as
INFERGEN · CIFN · rSIFN-co · consensus interferon · Recombinant Super-compound Interferon · IFN-alphacon1 · Infergen (interferon alfacon-1) · Interferon-alpha · +2 more
Regulatory milestones approvals, filings & regulatory actions · 2 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Withdrawn | EU (EMA) | Infergen | — | 2006-05-05 | europa.eu ↗ |
| Approved | EU (EMA) | Infergen | — | 1999-02-01 | europa.eu ↗ |
Trials 9
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT02464007 | Jan 2016 → Nov 2024 | neoplastic disease or syndrome | Sichuan Huiyang Life Science and Technology Corporation | Terminated | No outcome recorded |
| Phase 1 | NCT02387307 | Jul 2013 → Jun 2018 | colon carcinoma, hepatocellular carcinoma, melanoma, non-small cell lung carcinoma +1 | Sichuan Huiyang Life Science and Technology Corporation | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT07662278 | Jan 2027 → Jan 2030 expected | — | Sichuan Huiyang Life Science and Technology Corporation | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT05485584 | Jul 2022 → Apr 2023 | COVID-19 | Sichuan Huiyang Life Science and Technology Corporation | Completed | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT00162734 | Feb 2005 → Jun 2007 | chronic hepatitis C virus infection | Bausch Health Americas, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00086541 | Jun 2004 → Jan 2007 | chronic hepatitis C virus infection | Bausch Health Americas, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00239252 | — | hepatitis C virus infection | Astellas Pharma Inc | Completed | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT00456248 | Feb → Oct 2007 | chronic hepatitis C virus infection | Kadmon Corporation, LLC | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT00266318 | Dec 2005 → May 2007 | hepatitis C virus infection | Beth Israel Medical Center | Completed | No outcome recorded |
| Comparator or background therapy3 trials | ||||||
| Phase 1/2 | NCT01227798 Comparator | Nov 2010 → Nov 2011 | influenza | University Health Network, Toronto | Unknown | No outcome recorded |
| Phase 3 | NCT00211692 Comparator | Jul 2005 → Jul 2008 | chronic hepatitis C virus infection | Minneapolis Veterans Affairs Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT00207402 Background | Oct 2005 → Jan 2010 | hepatitis C virus infection | Brooke Army Medical Center | Completed | No outcome recorded |
Evidence & citations 13 cited values
Every value below carries the sentence it was read from. 13 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Interferon Alfacon-1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00211692 ↗ |
| Known as | CIFN | “Daily Infergen (Interferon Alfacon-1, CIFN) (9 or 15 µg) + Ribavirin (1000-1200 mg, based on body weight) PO Daily for up to 48 wks” NCT00086541 ↗3“Daily Infergen (Interferon Alfacon-1, CIFN) (9 or 15 µg) + Ribavirin (1000-1200 mg, based on body weight) PO Daily for up to 48 wks” NCT00162734 ↗ “consensus interferon (CIFN, CIFN or interferon alfacon-1) has greater antiviral activity in vitro” NCT00211692 ↗ “daily interferon alfacon-1 (Infergen, CIFN) at high dosage (24 mcg)” NCT00266318 ↗ |
| Known as | consensus interferon | “Consensus interferon for chronic hepatitis C patients with genotype 1 who failed to respond to, or relapsed after, interferon alpha-2b and ribavirin in combination: an Italian...” PMID 11984144 ↗ May 20021“consensus interferon (CIFN, CIFN or interferon alfacon-1) has greater antiviral activity in vitro” NCT00211692 ↗ |
| Known as | IFN-alphacon1 | “The Interferon-alpha (also called Interferon-alphacon1 or IFN-alphacon1 or INFERGEN) is an immune molecule” NCT01227798 ↗ |
| Known as | INFERGEN | “Daily Infergen (Interferon Alfacon-1, CIFN) (9 or 15 µg) + Ribavirin (1000-1200 mg, based on body weight) PO Daily for up to 48 wks” NCT00086541 ↗5“Daily Infergen (Interferon Alfacon-1, CIFN) (9 or 15 µg) + Ribavirin (1000-1200 mg, based on body weight) PO Daily for up to 48 wks” NCT00162734 ↗ “The Interferon-alpha (also called Interferon-alphacon1 or IFN-alphacon1 or INFERGEN) is an immune molecule” NCT01227798 ↗ “daily interferon alfacon-1 (Infergen, CIFN) at high dosage (24 mcg)” NCT00266318 ↗ “Infergen (interferon alfacon-1)” NCT00207402 ↗ |
| Known as | Infergen (interferon alfacon-1) | “Infergen (interferon alfacon-1)” NCT00207402 ↗ |
| Known as | Interferon-alpha | “The Interferon-alpha (also called Interferon-alphacon1 or IFN-alphacon1 or INFERGEN) is an immune molecule” NCT01227798 ↗ |
| Known as | Interferon-alphacon1 | “The Interferon-alpha (also called Interferon-alphacon1 or IFN-alphacon1 or INFERGEN) is an immune molecule” NCT01227798 ↗ |
| Known as | Recombinant Super-compound Interferon | “Recombinant Super-compound Interferon (rSIFN-co)” NCT05485584 ↗ |
| Known as | Recombinant-Compound Interferon (rSIFN-co) | “Recombinant-Compound Interferon (rSIFN-co)” NCT02387307 ↗ |
| Known as | rSIFN-co | “Recombinant Super-Compound Interferon (rSIFN-co)” NCT07662278 ↗ |
| Modality | Protein / enzyme biologic | “The Interferon-alpha (also called Interferon-alphacon1 or IFN-alphacon1 or INFERGEN) is an immune molecule” NCT01227798 ↗ |
| Route | Subcutaneous | “daily CIFN (15 mcg/day SQ)” NCT00211692 ↗ |